CD19-directed chimeric antigen receptor (CAR-T) T cells

BIOLOGICAL2 trials

Sponsors

Institute of Hematology & Blood Diseases Hospital, China

Conditions

Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)Ph- Acute Lymphoblastic Leukemia (Ph-ALL)

Phase 2

Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative B-ALL: A Prospective Umbrella Trial

Not yet recruitingNCT07643103

Institute of Hematology & Blood Diseases Hospital, ChinaPh- Acute Lymphoblastic Leukemia (Ph-ALL)

Start: 2026-06-12End: 2030-05-31Target: 32Updated: 2026-06-11

Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL

Not yet recruitingNCT07840976

Institute of Hematology & Blood Diseases Hospital, ChinaPh+ Acute Lymphoblastic Leukemia (Ph+ALL)

Start: 2026-10-12End: 2030-05-31Target: 22Updated: 2026-09-25